Gene Review:
NAT2 - N-acetyltransferase 2 (arylamine N...
Homo sapiens
Synonyms:
AAC2, Arylamide acetylase 2, Arylamine N-acetyltransferase 2, N-acetyltransferase type 2, NAT-2, ...
Kr??ger,
Phillips,
Karner-Hanusch,
Phromsopha,
Arlt,
Schwartz,
Muckel,
Fitzgibbons,
Skipper,
Pabel,
Sripa,
Pagenstecher,
Castelao,
R??schoff,
Farker,
Ross,
Hahnvajanawong,
Kukongviriyapan,
Bell,
Gago-Dominguez,
Glatt,
Bhudhisawasdi,
Sim,
Holinski-Feder,
Tassaneeyakul,
Kukongviriyapan,
Chen,
Scheele,
Mangold,
Hoffmann,
Chan,
Coetzee,
Moeslein,
Bell,
Sorg,
Doody,
Dupret,
Yu,
Watson,
Warshawsky,
Ricks,
Rodrigues-Lima,
Pistorius,
Mitchell,
Budge,
Tannenbaum,
Jonovska,
Porter,
Saeger,
Yuan,
Johnson,
Jay H. Lubin,
Manolis Kogevinas,
Debra Silverman,
Núria Malats,
Montserrat Garcia-Closas,
Adonina Tardón,
David W. Hein,
Reina Garcia-Closas,
Consol Serra,
Mustafa Dosemeci,
Alfredo Carrato,
Nathaniel Rothman,
von Knebel Doeberitz,
Schotte,
Engel,
G??rgens,
Schmeiser,
Schackert,
The German Hnpcc-Consortium,
- Analysis of candidate modifier loci for the severity of colonic familial adenomatous polyposis, with evidence for the importance of the N-acetyl transferases. Crabtree, M.D., Fletcher, C., Churchman, M., Hodgson, S.V., Neale, K., Phillips, R.K., Tomlinson, I.P. Gut (2004)
- NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. van der Hel, O.L., Peeters, P.H., Hein, D.W., Doll, M.A., Grobbee, D.E., Kromhout, D., Bueno de Mesquita, H.B. Pharmacogenetics (2003)
- A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Sachse, C., Smith, G., Wilkie, M.J., Barrett, J.H., Waxman, R., Sullivan, F., Forman, D., Bishop, D.T., Wolf, C.R. Carcinogenesis (2002)
- Metabolic activation of the environmental contaminant 3-nitrobenzanthrone by human acetyltransferases and sulfotransferase. Arlt, V.M., Glatt, H., Muckel, E., Pabel, U., Sorg, B.L., Schmeiser, H.H., Phillips, D.H. Carcinogenesis (2002)
- Effect of SULT1A1 and NAT2 genetic polymorphism on the association between cigarette smoking and colorectal adenomas. Tiemersma, E.W., Bunschoten, A., Kok, F.J., Glatt, H., de Boer, S.Y., Kampman, E. Int. J. Cancer (2004)
- A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer. Ochs-Balcom, H.M., Wiesner, G., Elston, R.C. Am. J. Epidemiol. (2007)
- Evidence for an intensity-dependent interaction of NAT2 acetylation genotype and cigarette smoking in the Spanish Bladder Cancer Study. Lubin, J.H., Kogevinas, M., Silverman, D., Malats, N., Garcia-Closas, M., Tardón, A., Hein, D.W., Garcia-Closas, R., Serra, C., Dosemeci, M., Carrato, A., Rothman, N. Int. J. Epidemiol (2007)
- NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant. Johnson, N., Bell, P., Jonovska, V., Budge, M., Sim, E. BMC Med. Genet. (2004)
- N-Acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk. Chen, C., Ricks, S., Doody, D.R., Fitzgibbons, E.D., Porter, P.L., Schwartz, S.M. Carcinogenesis (2001)
- Increased frequency of wild-type arylamine-N-acetyltransferase allele NAT2*4 homozygotes in Portuguese patients with colorectal cancer. Gil, J.P., Lechner, M.C. Carcinogenesis (1998)
- N-acetyltransferase (NAT) 2 acetylator status and age of onset in patients with hereditary nonpolyposis colorectal cancer (HNPCC). Pistorius, S., G??rgens, H., Kr??ger, S., Engel, C., Mangold, E., Pagenstecher, C., Holinski-Feder, E., Moeslein, G., von Knebel Doeberitz, M., R??schoff, J., Karner-Hanusch, J., Saeger, H.D., Schackert, H.K., The German Hnpcc-Consortium, n.u.l.l. Cancer Lett. (2006)
- Assessment of frequencies of lifestyle factors and polymorphisms of drug-metabolizing enzymes (NAT2, CYP2E1) in human hepatocellular carcinoma (HCC) patients in a department of surgical medicine--a pilot investigation. Farker, K., Schotte, U., Scheele, J., Hoffmann, A. International journal of clinical pharmacology and therapeutics. (2002)
- Molecular mechanisms of genetic polymorphisms of drug metabolism. Meyer, U.A., Zanger, U.M. Annu. Rev. Pharmacol. Toxicol. (1997)
- Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. Ambrosone, C.B., Freudenheim, J.L., Graham, S., Marshall, J.R., Vena, J.E., Brasure, J.R., Michalek, A.M., Laughlin, R., Nemoto, T., Gillenwater, K.A., Shields, P.G. JAMA (1996)
- Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders. Hirvonen, A., Saarikoski, S.T., Linnainmaa, K., Koskinen, K., Husgafvel-Pursiainen, K., Mattson, K., Vainio, H. J. Natl. Cancer Inst. (1996)
- A two-component nodule-specific enhancer in the soybean N23 gene promoter. Jørgensen, J.E., Stougaard, J., Marcker, K.A. Plant Cell (1991)
- Nuclear factors interact with conserved A/T-rich elements upstream of a nodule-enhanced glutamine synthetase gene from French bean. Forde, B.G., Freeman, J., Oliver, J.E., Pineda, M. Plant Cell (1990)
- Inhibitory effects of polyphenolic compounds on human arylamine N-acetyltransferase 1 and 2. Kukongviriyapan, V., Phromsopha, N., Tassaneeyakul, W., Kukongviriyapan, U., Sripa, B., Hahnvajanawong, V., Bhudhisawasdi, V. Xenobiotica (2006)
- Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients. Risch, A., Smelt, V., Lane, D., Stanley, L., van der Slot, W., Ward, A., Sim, E. Pharmacol. Toxicol. (1996)
- Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2. Dupret, J.M., Grant, D.M. J. Biol. Chem. (1992)
- Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Kinzig-Schippers, M., Tomalik-Scharte, D., Jetter, A., Scheidel, B., Jakob, V., Rodamer, M., Cascorbi, I., Doroshyenko, O., Sörgel, F., Fuhr, U. Antimicrob. Agents Chemother. (2005)
- Orofacial clefts and spina bifida: N-acetyltransferase phenotype, maternal smoking, and medication use. van Rooij, I.A., Groenen, P.M., van Drongelen, M., Te Morsche, R.H., Peters, W.H., Steegers-Theunissen, R.P. Teratology (2002)
- p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. Schroeder, J.C., Conway, K., Li, Y., Mistry, K., Bell, D.A., Taylor, J.A. Cancer Res. (2003)
- Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Brockmöller, J., Cascorbi, I., Kerb, R., Roots, I. Cancer Res. (1996)
- Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Grant, D.M., Blum, M., Beer, M., Meyer, U.A. Mol. Pharmacol. (1991)
- Stable expression of human CYP1A2 and N-acetyltransferases in Chinese hamster CHL cells: mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline and 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline. Yanagawa, Y., Sawada, M., Deguchi, T., Gonzalez, F.J., Kamataki, T. Cancer Res. (1994)
- Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression. Williams, J.A. Carcinogenesis (2001)
- N-Acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast. Williams, J.A., Stone, E.M., Fakis, G., Johnson, N., Cordell, J.A., Meinl, W., Glatt, H., Sim, E., Phillips, D.H. Pharmacogenetics (2001)
- Basal and induced micronucleus frequencies in human lymphocytes with different GST and NAT2 genetic backgrounds. Hernández, A., Xamena, N., Gutiérrez, S., Velázquez, A., Creus, A., Surrallés, J., Galofré, P., Marcos, R. Mutat. Res. (2006)
- The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Windmill, K.F., McKinnon, R.A., Zhu, X., Gaedigk, A., Grant, D.M., McManus, M.E. Mutat. Res. (1997)
- Carotenoids/vitamin C and smoking-related bladder cancer. Castelao, J.E., Yuan, J.M., Gago-Dominguez, M., Skipper, P.L., Tannenbaum, S.R., Chan, K.K., Watson, M.A., Bell, D.A., Coetzee, G.A., Ross, R.K., Yu, M.C. Int. J. Cancer (2004)
- Expression of cytochromes P450 and glutathione S-transferases in human prostate, and the potential for activation of heterocyclic amine carcinogens via acetyl-coA-, PAPS- and ATP-dependent pathways. Di Paolo, O.A., Teitel, C.H., Nowell, S., Coles, B.F., Kadlubar, F.F. Int. J. Cancer (2005)
- DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Matullo, G., Guarrera, S., Carturan, S., Peluso, M., Malaveille, C., Davico, L., Piazza, A., Vineis, P. Int. J. Cancer (2001)
- Regulation of the activity of the human drug metabolizing enzyme arylamine N-acetyltransferase 1: role of genetic and non genetic factors. Rodrigues-Lima, F., Dupret, J.M. Curr. Pharm. Des. (2004)
- Activation of heterocyclic amines by combinations of prostaglandin H synthase-1 and -2 with N-acetyltransferase 1 and 2. Liu, Y., Levy, G.N. Cancer Lett. (1998)
- Xenobiotic inducible regions of the human arylamine N-acetyltransferase 1 and 2 genes. Mitchell, K.R., Warshawsky, D. Toxicol. Lett. (2003)
- Low CYP1A2 activity associated with testicular cancer. Vistisen, K., Loft, S., Olsen, J.H., Vallentin, S., Ottesen, S., Hirsch, F.R., Poulsen, H.E. Carcinogenesis (2004)
- Variability and validity of polymorphism association studies in Parkinson's disease. Tan, E.K., Khajavi, M., Thornby, J.I., Nagamitsu, S., Jankovic, J., Ashizawa, T. Neurology (2000)
- Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Lemos, M.C., Cabrita, F.J., Silva, H.A., Vivan, M., Plácido, F., Regateiro, F.J. Carcinogenesis (1999)
- Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Firozi, P.F., Bondy, M.L., Sahin, A.A., Chang, P., Lukmanji, F., Singletary, E.S., Hassan, M.M., Li, D. Carcinogenesis (2002)
- Association of genotypes of carcinogen-activating enzymes, phenol sulfotransferase SULT1A1 (ST1A3) and arylamine N-acetyltransferase NAT2, with urothelial cancer in a Japanese population. Ozawa, S., Katoh, T., Inatomi, H., Imai, H., Kuroda, Y., Ichiba, M., Ohno, Y. Int. J. Cancer (2002)
- Arylamine N-acetyltransferase type 2 (NAT2), chromosome 8 aneuploidy, and identification of a novel NAT1 cosmid clone: an investigation in bladder cancer by interphase FISH. Stacey, M., Matas, N., Drake, M., Payton, M., Fakis, G., Greenland, J., Sim, E. Genes Chromosomes Cancer (1999)
- Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Okkels, H., Sigsgaard, T., Wolf, H., Autrup, H. Cancer Epidemiol. Biomarkers Prev. (1997)
- Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Hamdy, S.I., Hiratsuka, M., Narahara, K., Endo, N., El-Enany, M., Moursi, N., Ahmed, M.S., Mizugaki, M. British journal of clinical pharmacology. (2003)